Tianyi Medical Co., Ltd.

Announcement on the Implementation of 2025 Annual Equity Distribution

Legal Opinion Letter for the 2025 Annual Shareholders' Meeting

Announcement of Resolutions from the 2025 Annual Shareholders' Meeting

Announcement on the Progress of Share Repurchase

Announcement on the Company's Receipt of the 'Administrative Penalty Decision' from the Ningbo Market Supervision Administration

Guotai Junan Securities Co., Ltd. Sponsorship Summary Report on the Initial Public Offering and Listing on the Growth Enterprise Market of Ningbo Tianyi Medical Devices Co., Ltd.

Guotai Junan Securities Co., Ltd. Special Verification Opinion on the Storage and Use of Fundraising by Ningbo Tianyi Medical Devices Co., Ltd. in 2025

Guotai Junan Securities Co., Ltd. Verification Opinion on the Use of Part of the Idle Fundraising for Cash Management by Ningbo Tianyi Medical Devices Co., Ltd.

Guotai Junan Securities Co., Ltd. On-Site Inspection Report on Continuous Supervision Work for Ningbo Tianyi Medical Devices Co., Ltd. in 2025

Guotai Junan Securities Co., Ltd. Report on Continuous Supervision Training for Ningbo Tianyi Medical Devices Co., Ltd. in 2025

Announcement on the Reappointment of the Accounting Firm

Guotai Junan Securities Co., Ltd. Continuous Supervision Tracking Report for Ningbo Tianyi Medical Devices Co., Ltd. in 2025

Independent Director 2025 Work Report - Zheng Yifeng

Independent Director 2025 Work Report - Liu Qigui

Independent Director 2025 Work Report - Zhang Dingbiao

Announcement on Holding the 2025 Online Performance Briefing

Guotai Junan Securities Co., Ltd. Verification Opinion on Ningbo Tianyi Medical Devices Co., Ltd. '2025 Internal Control Self-Evaluation Report'

Tianyi Medical - Internal Control Audit Report

2025 Internal Control Self-Evaluation Report

Tianyi Medical - Compensation Management System for Directors and Senior Management

Ningbo Tianyi Medical Devices Co., Ltd. 2025 Financial Report

Announcement on the Company's and Subsidiaries' Application for Comprehensive Credit Limits from Banks

2025 Financial Settlement Report

2025 Board of Directors Work Report

2025 Goodwill Impairment Test Report

Special Report on the Management and Use of Fundraising in 2025

Feasibility Analysis on the Development of Foreign Exchange Hedging Business

Announcement on the Development of Foreign Exchange Hedging Business

Notice of the 2025 Annual Shareholders' Meeting

Announcement of the Resolution of the Fifth Meeting of the Fourth Board of Directors

Announcement on the Profit Distribution Plan for 2025

Q1 2026 Report

2025 Special Report on Fundraising for Tianyi Medical

Special Verification Opinion on Revenue Deduction for Tianyi Medical

Report on the Evaluation of the Performance of the Accounting Firm for 2025 and the Report on the Audit Committee's Supervision Responsibilities

Special Audit Explanation on Non-Operating Fund Occupation and Other Related Fund Transactions for Tianyi Medical in 2025

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions

Special Opinion of the Board of Directors on the Independence of Independent Directors

2025 Annual Audit Report

2025 Annual Report

2025 Annual Report Summary

Guotai Junan Securities Co., Ltd. on the verification opinions regarding Ningbo Tianyi Medical Equipment Co., Ltd.'s use of part of the idle raised funds for cash management

Announcement on the use of part of the idle raised funds and self-owned funds for cash management

Announcement on the Company's Receipt of the Administrative Penalty Notice from Ningbo Market Supervision Administration

Announcement on the Company’s New Product Obtaining Drug Registration Certificate

Announcement on providing guarantees for wholly-owned subsidiary

Announcement of resolutions from the 4th meeting of the 4th Board of Directors

Announcement on the progress of the company's share repurchase

Legal opinion on the first extraordinary general meeting of shareholders in 2026

Announcement on the resolutions of the first extraordinary general meeting of shareholders in 2026

Announcement on Repurchase of Company Shares Reaching 1% and Repurchase Progress

Announcement on the Company's New Product Obtaining a Drug Registration Certificate

Announcement on the First Repurchase of Company Shares and the Progress of Share Repurchase

Announcement on Estimated Daily Related Party Transactions for 2026

Notice of Convening the First Extraordinary General Meeting of Shareholders in 2026

Resolution Announcement of the Third Meeting of the Fourth Board of Directors

Announcement on the Company's New Product Obtaining a Drug Registration Certificate

Announcement on the Change of Sponsor Representative